These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
371 related articles for article (PubMed ID: 9419975)
1. Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4. Komurasaki T; Toyoda H; Uchida D; Morimoto S Oncogene; 1997 Dec; 15(23):2841-8. PubMed ID: 9419975 [TBL] [Abstract][Full Text] [Related]
2. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin. Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426 [TBL] [Abstract][Full Text] [Related]
3. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells. Huang Y; Li X; Jiang J; Frank SJ Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991 [TBL] [Abstract][Full Text] [Related]
4. Differential heat stress stability of epidermal growth factor receptor and erbB-2 receptor tyrosine kinase activities. Liu SM; Carpenter G J Cell Physiol; 1993 Nov; 157(2):237-42. PubMed ID: 7901224 [TBL] [Abstract][Full Text] [Related]
5. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. Ram TG; Ethier SP Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665 [TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2. Ram TG; Dilts CA; Dziubinski ML; Pierce LJ; Ethier SP Mol Carcinog; 1996 Mar; 15(3):227-38. PubMed ID: 8597535 [TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors. Alimandi M; Wang LM; Bottaro D; Lee CC; Kuo A; Frankel M; Fedi P; Tang C; Lippman M; Pierce JH EMBO J; 1997 Sep; 16(18):5608-17. PubMed ID: 9312020 [TBL] [Abstract][Full Text] [Related]
8. Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor. Azios NG; Romero FJ; Denton MC; Doherty JK; Clinton GM Oncogene; 2001 Aug; 20(37):5199-209. PubMed ID: 11526509 [TBL] [Abstract][Full Text] [Related]
9. Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta. Riese DJ; Bermingham Y; van Raaij TM; Buckley S; Plowman GD; Stern DF Oncogene; 1996 Jan; 12(2):345-53. PubMed ID: 8570211 [TBL] [Abstract][Full Text] [Related]
10. Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR. Dittmar T; Husemann A; Schewe Y; Nofer JR; Niggemann B; Zänker KS; Brandt BH FASEB J; 2002 Nov; 16(13):1823-5. PubMed ID: 12354693 [TBL] [Abstract][Full Text] [Related]
11. ErbB kinases and NDF signaling in human prostate cancer cells. Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997 [TBL] [Abstract][Full Text] [Related]
12. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Motoyama AB; Hynes NE; Lane HA Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928 [TBL] [Abstract][Full Text] [Related]
13. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. Karunagaran D; Tzahar E; Beerli RR; Chen X; Graus-Porta D; Ratzkin BJ; Seger R; Hynes NE; Yarden Y EMBO J; 1996 Jan; 15(2):254-64. PubMed ID: 8617201 [TBL] [Abstract][Full Text] [Related]
14. An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells. Grant SL; Hammacher A; Douglas AM; Goss GA; Mansfield RK; Heath JK; Begley CG Oncogene; 2002 Jan; 21(3):460-74. PubMed ID: 11821958 [TBL] [Abstract][Full Text] [Related]
15. Feedback inhibition by RALT controls signal output by the ErbB network. Anastasi S; Fiorentino L; Fiorini M; Fraioli R; Sala G; Castellani L; Alemà S; Alimandi M; Segatto O Oncogene; 2003 Jul; 22(27):4221-34. PubMed ID: 12833145 [TBL] [Abstract][Full Text] [Related]
16. Human corneal epithelial cell proliferation by epiregulin and its cross-induction by other EGF family members. Morita S; Shirakata Y; Shiraishi A; Kadota Y; Hashimoto K; Higashiyama S; Ohashi Y Mol Vis; 2007 Nov; 13():2119-28. PubMed ID: 18079685 [TBL] [Abstract][Full Text] [Related]
17. Bivalence of EGF-like ligands drives the ErbB signaling network. Tzahar E; Pinkas-Kramarski R; Moyer JD; Klapper LN; Alroy I; Levkowitz G; Shelly M; Henis S; Eisenstein M; Ratzkin BJ; Sela M; Andrews GC; Yarden Y EMBO J; 1997 Aug; 16(16):4938-50. PubMed ID: 9305636 [TBL] [Abstract][Full Text] [Related]
18. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466 [TBL] [Abstract][Full Text] [Related]
19. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo. Yang D; Kuan CT; Payne J; Kihara A; Murray A; Wang LM; Alimandi M; Pierce JH; Pastan I; Lippman ME Clin Cancer Res; 1998 Apr; 4(4):993-1004. PubMed ID: 9563895 [TBL] [Abstract][Full Text] [Related]